Theratechnologies Inc
TSX:TH

Watchlist Manager
Theratechnologies Inc Logo
Theratechnologies Inc
TSX:TH
Watchlist
Price: 4.495 CAD -0.33% Market Closed
Market Cap: 206.7m CAD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one TH stock under the Base Case scenario is 4.152 CAD. Compared to the current market price of 4.495 CAD, Theratechnologies Inc is Overvalued by 8%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TH Relative Value
Base Case
4.152 CAD
Overvaluation 8%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.8
P/S
P/S
Price to Sales
1.8
vs History
47
vs Industry
87
Median 3Y
1
Median 5Y
1.7
Industry
7.7
Forward
1.8
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-8.1
Median 5Y
-16.9
Industry
22.9
Forward
-157.7
More Details
21.2
P/OCF
P/OCF
Price to OCF
21.2
vs History
4
vs Industry
6
Median 3Y
-13.1
Median 5Y
-51
Industry
21.5
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-9.5
Industry
22.7
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-2.4
Industry
3
More Details
2.1
EV/S
EV/S
Enterprise Value to Sales
2.1
vs History
47
vs Industry
73
Median 3Y
1.1
Median 5Y
2.1
Industry
8.2
Forward
2.1
More Details
2.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.7
vs History
47
vs Industry
73
Median 3Y
1.5
Median 5Y
2.7
Industry
10.4
More Details
17.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
17.2
vs History
0
vs Industry
12
Median 3Y
-2
Median 5Y
-14.8
Industry
5.6
Forward
14.5
More Details
21.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
21.2
vs History
0
vs Industry
10
Median 3Y
-1.5
Median 5Y
-9.1
Industry
5.9
Forward
16.1
More Details
25.5
EV/OCF
EV/OCF
Enterprise Value to OCF
25.5
vs History
4
vs Industry
4
Median 3Y
-15
Median 5Y
-53.5
Industry
6.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
1
Median 3Y
-11.5
Median 5Y
-49.3
Industry
5
More Details
9.8
EV/IC
EV/IC
Enterprise Value to IC
9.8
vs History
53
vs Industry
28
Median 3Y
8.6
Median 5Y
13
Industry
5.2
More Details

Multiples Across Competitors

TH Competitors Multiples
Theratechnologies Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Theratechnologies Inc
TSX:TH
206.7m CAD 1.8 -16.3 17.2 21.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 071 784.8 -161 938.1 -196 644.6 -194 400.6
US
Abbvie Inc
NYSE:ABBV
367.6B USD 6.3 98.7 16.2 23.6
US
US BioTec Inc
OTC:USBC
168.1B USD 0 0 0 0
US
Amgen Inc
NASDAQ:AMGN
154.7B USD 4.4 23.4 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
141.7B USD 4.9 22.5 10.5 14.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.7 -527.6 -574.5 -559.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
99.5B USD 8.7 27.4 20.1 21
AU
CSL Ltd
ASX:CSL
104.4B AUD 4.4 22.6 14.9 18.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
62.4B USD 4.4 14 12.6 14.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
59.5B USD 24.1 -186.3 -465.8 -319.8
P/S Multiple
Revenue Growth P/S to Growth
CA
Theratechnologies Inc
TSX:TH
Average P/S: 3 407 391.2
1.8
6%
0.3
FR
Pharnext SCA
OTC:PNEXF
34 071 784.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.3
9%
0.7
US
U
US BioTec Inc
OTC:USBC
Not Available N/A N/A
US
Amgen Inc
NASDAQ:AMGN
4.4
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.9
4%
1.2
US
E
Epizyme Inc
F:EPE
2 067.7
N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
8.7
10%
0.9
AU
CSL Ltd
ASX:CSL
4.4
6%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.4
5%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
24.1
41%
0.6
P/E Multiple
Earnings Growth PEG
CA
Theratechnologies Inc
TSX:TH
Average P/E: 34.8
Negative Multiple: -16.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 938.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
98.7
88%
1.1
US
U
US BioTec Inc
OTC:USBC
Not Available N/A N/A
US
Amgen Inc
NASDAQ:AMGN
23.4
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
22.5
191%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.6 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.4
N/A N/A
AU
CSL Ltd
ASX:CSL
22.6
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14
6%
2.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -186.3 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Theratechnologies Inc
TSX:TH
Average EV/EBITDA: 15.7
17.2
47%
0.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 644.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.2
14%
1.2
US
U
US BioTec Inc
OTC:USBC
Not Available N/A N/A
US
Amgen Inc
NASDAQ:AMGN
18.3
10%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.5
6%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.5 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.1
17%
1.2
AU
CSL Ltd
ASX:CSL
14.9
12%
1.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.6
9%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -465.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
Theratechnologies Inc
TSX:TH
Average EV/EBIT: 18.8
21.2
55%
0.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 400.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.6
28%
0.8
US
U
US BioTec Inc
OTC:USBC
Not Available N/A N/A
US
Amgen Inc
NASDAQ:AMGN
18.3
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.4
12%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.2 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21
17%
1.2
AU
CSL Ltd
ASX:CSL
18.6
16%
1.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.2
10%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -319.8 N/A N/A

See Also

Summary
TH intrinsic value, competitors valuation, and company profile.
DCF Valuation
TH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TH stock valuation using valuation multiples.
Wall Street Estimates
TH price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 278,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.